Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Depressive Symptoms and Amyloid Pathology
Oomens, Julie Elisabeth , Engelborghs, Sebastiaan , Arnim, Christine A. F. Von , Boada, Merçé , Didic, Mira , Dubois, Bruno, Fröhlich, Lutz, Gill, Kiran Dip, Grimmer, Timo, Hildebrandt, Helmut , Itoh, Yoshiaki , Lee, Dong Young , Lleó, Alberto, Meyer, Philipp T. , Kapaki, Elisabeth, Pardini, Matteo , Popp, Julius , Rami, Lorena , Reiman, Eric M. , Rinne, Juha O. , Sánchez‐Juan, Pascual, Sarazin, Marie , Scarmeas, Nikolaos , Villeneuve, Sylvia , Wallin, Anders, Vos, Stephanie J. B. , Jansen, Willemijn J. , group, Amyloid Biomarker Study, Altomare, Daniele , Baldeiras, Inês , Blennow, Kaj, Braber, Anouk den , Cerman, Jiří , Chipi, Elena , Eckerström, Marie , Ekblad, Laura L. , Förster, Stefan , Guedj, Éric , Hausner, Lucrezia , Huey, Edward D. , Jiménez‐Bonilla, J., Johnson, Keith A. , Juaristi, Arantxa, Kern, Silke , Kirsebom, Bjørn‐Eivind , Landau, Susan , Legdeur, Nienke , Guerra, Jorge J. Llibre, Maserejian, Nancy N., Marquié, Marta , Minatani, Shinobu, Olivieri, Pauline , Perrin, Richard J., Peters, Oliver , Prabhakar, Sudesh, Ramakers, Inez H., Rodríguez‐Rodríguez, Eloy , Ruiz, Agustín, Rüther, E., Selnes, Per , Spiru, Luiza , Takeda, Akitoshi , Teichmann, Marc , Thompson, Loisa I., Vogelgsangs, Jonathan, Wallin, Åsa K., Zettergren, Anna , Frisoni, Giovanni B. , Boada, Merce , Oomens, Julie E , Bottlaender, Michel , Wiels, Wietse A. , Baeken, Chris , Dubois, Bruno , Fladby, Tormod , Flier, Wiesje M. van der , Frisoni, Giovanni B. , Fröhlich, Lutz, Grimmer, Timo , Hort, Jakub , Iwatsubo, Takeshi , Klimkowicz‐Mrowiec, Aleksandra , Lleó, Alberto , Martínez‐Lage, Pablo , Mendonça, Alexandre de , Parchi, Piero , Parnetti, Lucilla , Rodrigue, Karen M. , Santana, Isabel , Skoog, Ingmar , Snyder, Peter J. , Sperling, Reisa Anne , Wiltfang, Jens , Zetterberg, Henrik , Ossenkoppele, Rik , Verhey, Frans R.J. , Visser, Pieter Jelle , Alcolea, Daniel , Baiardi, Simone , Bateman, Randall J. , Blennow, Kaj , Buchem, Mark A. van , Byun, Min Soo , Chen, Kewei , Day, Gregory S. , Drzezga, Alexander E. , Epelbaum, Stéphane , Fortea, Juan , Freund‐Levi, Yvonne , Frings, Lars , Hellwig, Sabine , Kandimalla, Ramesh , Paraskevas, George P. , Kornhuber, Johannes , Lagarde, Julien , Morbelli, Silvia , Mroczko, Barbara , Ntanasi, Eva , Oliveira, Catarina Resende , Olivieri, Pauline , Orellana, Adelina , Ruiz, Agustı́n , Silva, Dina , Soininen, Hilkka S. , Tijms, Betty M. , Teunissen, Charlotte E. , Vöglein, Jonathan , Waldemar, Gunhild , Yannakoulia, Mary , Yi, Dahyun

Mayo Clinic

JAMA Psychiatry | January 22, 2025 | Volume: 82 | Issue: 3 | Pages: 296

10.1001/jamapsychiatry.2024.4305 | PMID 39841452 Get It

Importance Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology. Objective To examine the association between depressive symptoms and amyloid pathology and its dependency on age, sex, education, and APOE genotype in older individuals without dementia. Design, Setting, and Participants Cross-sectional analyses were performed using data from the Amyloid Biomarker Study data pooling initiative. Data from 49 research, population-based, and memory clinic studies were pooled and harmonized. The Amyloid Biomarker Study has been collecting data since 2012 and data collection is ongoing. At the time of analysis, 95 centers were included in the Amyloid Biomarker Study. The study included 9746 individuals with normal cognition (NC) and 3023 participants with mild cognitive impairment (MCI) aged between 34 and 100 years for whom data on amyloid biomarkers, presence of depressive symptoms, and age were available. Data were analyzed from December 2022 to February 2024. Main Outcomes and Measures Amyloid-β1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were used to determine presence or absence of amyloid pathology. Presence of depressive symptoms was determined on the basis of validated depression rating scale scores, evidence of a current clinical diagnosis of depression, or self-reported depressive symptoms. Results In individuals with NC (mean [SD] age, 68.6 [8.9] years; 5664 [58.2%] female; 3002 [34.0%] APOE ε4 carriers; 937 [9.6%] had depressive symptoms; 2648 [27.2%] had amyloid pathology), the presence of depressive symptoms was not associated with amyloid pathology (odds ratio [OR], 1.13; 95% CI, 0.90-1.40; P = .29). In individuals with MCI (mean [SD] age, 70.2 [8.7] years; 1481 [49.0%] female; 1046 [44.8%] APOE ε4 carriers; 824 [27.3%] had depressive symptoms; 1668 [55.8%] had amyloid pathology), the presence of depressive symptoms was associated with a lower likelihood of amyloid pathology (OR, 0.73; 95% CI 0.61-0.89; P = .001). When considering subgroup effects, in individuals with NC, the presence of depressive symptoms was associated with a higher frequency of amyloid pathology in APOE ε4 noncarriers (mean difference, 5.0%; 95% CI 1.0-9.0; P = .02) but not in APOE ε4 carriers. This was not the case in individuals with MCI. Conclusions and Relevance Depressive symptoms were not consistently associated with a higher frequency of amyloid pathology in participants with NC and were associated with a lower likelihood of amyloid pathology in participants with MCI. These findings were not influenced by age, sex, or education level. Mechanisms other than amyloid accumulation may commonly underlie depressive symptoms in late life.
Transcatheter Pulmonary Flow Restrictors as a Palliative Bridge to Heart Transplant
Masilamani, Mats Steffi Jennifer , Johnson, Jonathan N. , Ameduri, Rebecca , Stephens, Elizabeth H. , Cabalka, Allison K. , Anderson, Jason H. , Ameduri, Rebecca K , Cabalka, Allison , Anderson, Jason

Mayo Clinic

Pediatric Transplantation | January 21, 2025 | Volume: 29 | Issue: 1 | Pages: No page available

10.1111/petr.70025 | PMID 39837668 Get It

ABSTRACT Background In recent years, transcatheter implantation devices to restrict pulmonary arterial flow have emerged as a potential alternative to surgical pulmonary artery banding. Case Presentation A term male was diagnosed with critical aortic stenosis (AS) and severely reduced left ventricle (LV) systolic function. He underwent aortic balloon valvuloplasty on day 2 of life, resulting in some antegrade flow, but LV ejection fraction only improved to 15%. He remained ductal dependent for systemic perfusion. Pulmonary over‐circulation ensued with systemic steal evident in his second week of life. On day 14, he underwent a transcatheter stage 1 procedure including the placement of bilateral pulmonary flow restrictor (PFR) devices and ductal stenting. Post‐procedure, he improved clinically, weaned off respiratory support, and transitioned to oral feeds while awaiting cardiac transplant. Twelve days later, he received a donor heart, with an uneventful recovery. He is now 3 years post‐transplant and has excellent graft function, and his transplant course has been unremarkable. Conclusion Transcatheter‐based palliation for a neonate with critical AS, utilizing endoluminal PFRs, proved effective in stabilizing the infant and successfully bridging him to transplant. This highlights an opportunity for the utilization of PFRs in neonatal conditions where control of pulmonary blood flow is imperative as a bridge to transplantation.
Molecular Imaging of Paragangliomas and Pheochromocytomas
Burkett, Brian J. , Johnson, Derek R. , Johnson, Derek R , Burkett, Brian

Mayo Clinic

Radiology: Imaging Cancer | January 21, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1148/rycan.240440 | PMID 39836079 Get It

ASRA Pain Medicine consensus practice infection control guidelines for regional anesthesia and pain medicine
Provenzano, David , Hanes, Michael, Hunt, Christine , Benzon, Honorio T. , Grider, Jay S., Cawcutt, Kelly , Doshi, Tina L , Hayek, Salim M. , Hoeltzer, Bryan, Johnson, Rebecca L. , Macfarlane, Alan , Neuman, Stephanie, Pawa, Amit , Pilitsis, Julie G. , Sivanesan, Eellan , Sondekoppam, Rakesh V. , Zundert, Jan Van , Provenzano, David Anthony , Hayek, Salim , Kopp, Sandra , Loftus, Randy W. , Macfarlane, Alan James Robert , Nagpal, Ameet S , Neuman, Stephanie A , Pawa, Amit , Pearson, Amy C S , Sivanesan, Eellan , Sondekoppam, Rakesh V , van Zundert, Jan , Narouze, Samer , Benzon, Honorio T , Cawcutt, Kelly , Johnson, Rebecca L , Doshi, Tina L , Hunt, Christine , Grider, Jay S. , Kalagara, Hari , Kopp, Sandra L. , Nagpal, Ameet , Pearson, Amy C. S. , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2024-105651

10.1136/rapm-2024-105651 | PMID 39837579 Get It

Background To provide recommendations on risk mitigation, diagnosis and treatment of infectious complications associated with the practice of regional anesthesia, acute and chronic pain management. Methods Following board approval, in 2020 the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) commissioned evidence-based guidelines for best practices for infection control. More than 80 research questions were developed and literature searches undertaken by assigned working groups comprising four to five members. Modified US Preventive Services Task Force criteria were used to determine levels of evidence and certainty. Using a modified Delphi method, >50% agreement was needed to accept a recommendation for author review, and >75% agreement for a recommendation to be accepted. The ASRA Pain Medicine Board of Directors reviewed and approved the final guidelines. Results After documenting the incidence and infectious complications associated with regional anesthesia and interventional pain procedures including implanted devices, we made recommendations regarding the role of the anesthesiologist and pain physician in infection control, preoperative patient risk factors and management, sterile technique, equipment use and maintenance, healthcare setting (office, hospital, operating room), surgical technique, postoperative risk reduction, and infection symptoms, diagnosis, and treatment. Consensus recommendations were based on risks associated with different settings and procedures, and keeping in mind each patient’s unique characteristics. Conclusions The recommendations are intended to be multidisciplinary guidelines for clinical care and clinical decision-making in the regional anesthesia and chronic interventional pain practice. The issues addressed are constantly evolving, therefore, consistent updating will be required.
Blood Culture Use in Medical and Surgical Intensive Care Units and Wards
Hsu, Yea‐Jen , Salinas, Alejandra , Gadala, Avinash , Bower, Chris , Degnan, Kathleen, Dhaubhadel, Pragya, Drees, Marci , Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glaser, Laurel , Johnson, J. Kristie, Kim, Justin , Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Robinson, Evan D. , Rodriguez‐Nava, Guillermo , Salinas, Jorge , Schrank, Gregory M. , Shah, Aditya , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Cosgrove, Sara E. , Fabre, Valeria , Carroll, Karen C. , Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Howard‐Anderson, Jessica , Mathers, Amy J. , Moehring, Rebekah W. , Nelson, George E. , O’Horo, John C. , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van

Mayo Clinic

JAMA Network Open | January 15, 2025 | Volume: 8 | Issue: 1 | Pages: e2454738

10.1001/jamanetworkopen.2024.54738 | PMID 39813030 Get It

ImportanceBlood culture (BC) use benchmarks in US hospitals have not been defined.ObjectiveTo characterize BC use in adult intensive care units (ICUs) and wards in US hospitals.Design, Setting, and ParticipantsA retrospective cross-sectional study of BC use in adult medical ICUs, medical-surgical ICUs, medical wards, and medical-surgical wards from acute care hospitals from the 4 US geographic regions was conducted. Critical access hospitals, less than 6 months of BC data, and non-US hospitals were excluded. The study included BC use data from September 1, 2019, to August 31, 2021. Data were analyzed from February 23 to July 14, 2024.Main Outcomes and MeasuresThe primary outcome was BC use per 1000 patient-days. Adjusted means with 95% CIs were calculated using mixed-effects negative binomial regression models adjusted for unit type, hospital bed size, geographic region, seasonality, and state COVID-19 case load, with random intercepts accounting for clustering at unit and hospital levels. Secondary outcomes included blood culture positivity, single BCs, BC contamination, and minimum threshold for BC use where blood culture positivity would be optimized.ResultsA total of 362 327 blood cultures were analyzed from 27 medical ICUs, 35 medical-surgical ICUs, 121 medical wards, and 109 medical-surgical wards from 48 hospitals in 19 states and the District of Columbia. The adjusted mean BC use per 1000 patient-days was 273.1 (95% CI, 270.2-275.9) for medical ICUs, 146.0 (95% CI, 144.5-147.5) for medical-surgical ICUs, 80.3 (95% CI, 79.8-80.7) for medical wards, and 65.1 for medical-surgical wards. Blood culture use was significantly higher across all 4 unit types in hospitals with more than 500 beds compared with 500 or less beds and in the West-Midwest compared with other regions. Single blood culture and positive blood culture rates were below 10% across all 4 unit types. Of the 292 units, 97% had a mean BC contamination rate within 3% of the recommended threshold, and 51% were within 1%. The minimum BC use thresholds (ie, BC use below this number may represent undertesting) were 120 BCs per 1000 patient-days for medical ICUs, 80 BCs per 1000 patient-days for medical-surgical ICUs, and 30 BCs per 1000 patient-days for medical-surgical wards.Conclusions and RelevanceThe findings of this study suggest that blood culture positivity may help determine appropriate BC use for individual unit types.
Abstract 385: Rapid Development of Diffuse Subcutaneous Hematomas Following IV Alteplase
Johnson, D. Gale , Johnson, D.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | January 15, 2025 | Volume: 4 | Issue: S1 | Pages: No page available

10.1161/svin.04.suppl_1.385 Get It

Abstract 413: Stroke in young: A nefarious combination of binge alcohol consumption with energy drinks
Dweik, Khaled, Ransick, Joshua, Johnson, Derek R. , Chaudhary, H., Ranasinghe, T.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | January 15, 2025 | Volume: 4 | Issue: S1 | Pages: No page available

10.1161/svin.04.suppl_1.413 Get It

Assessing ChatGPT's Capability in Addressing Thyroid Cancer Patient Queries: A Comprehensive Mixed-Methods Evaluation
Gorris, Matthew A. , Randle, Reese W. , Obermiller, Corey , Thomas, Johnson, Toro-Tobón, David , Dream, Sophie , Fackelmayer, Oliver J. , Pandian, T.K. , Mayson, Sarah E. , Toro-Tobon, David

Mayo Clinic

Journal of the Endocrine Society | January 13, 2025 | Volume: 9 | Issue: 2 | Pages: No page available

10.1210/jendso/bvaf003 | PMID 39881674 Get It

Abstract Context Literature suggests patients with thyroid cancer have unmet informational needs in many aspects of care. Patients often turn to online resources for their health-related information, and generative artificial intelligence programs such as ChatGPT are an emerging and attractive resource for patients. Objective To assess the quality of ChatGPT's responses to thyroid cancer-related questions. Methods Four endocrinologists and 4 endocrine surgeons, all with expertise in thyroid cancer, evaluated the responses to 20 thyroid cancer-related questions. Responses were scored on a 7-point Likert scale in areas of accuracy, completeness, and overall satisfaction. Comments from the evaluators were aggregated and a qualitative analysis was performed. Results Overall, only 57%, 56%, and 52% of the responses “agreed” or “strongly agreed” that ChatGPT's answers were accurate, complete, and satisfactory, respectively. One hundred ninety-eight free-text comments were included in the qualitative analysis. The majority of comments were critical in nature. Several themes emerged, which included overemphasis of diet and iodine intake and its role in thyroid cancer, and incomplete or inaccurate information on risks of both thyroid surgery and radioactive iodine therapy. Conclusion Our study suggests that ChatGPT is not accurate or reliable enough at this time for unsupervised use as a patient information tool for thyroid cancer.
Patient-reported outcome trajectories the first 24 months after surgery for cervical spondylotic myelopathy: a Quality Outcomes Database study
Zeitouni, Daniel , Johnson, Sarah E. , Bisson, Erica F. , Mummaneni, Praveen V., Haid, Regis W., Chan, Andrew K. , Chou, Dean , Wang, Michael Y. , Knightly, John J. , Meyer, Scott A., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S. , Fu, Kai-Ming, Shaffrey, Mark E., Foley, Kevin T. , Upadhyaya, Cheerag D., Potts, Eric A. , Turner, Jay D. , Uribe, Juan S. , Tumialán, Luis M. , Coric, Domagoj , Bydon, Mohamad , Asher, Anthony L. , Ibrahim, Sufyan , Mummaneni, Praveen V. , Shaffrey, Christopher I. , Fu, Kai-Ming, Park, Paul , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | January 10, 2025 | Volume: 42 | Issue: 4 | Pages: 500-508

10.3171/2024.9.spine24351 | PMID 39793008 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) shows varying levels of improvement after surgical treatment. While some patients improve soon after surgery, others may take months to years to show any signs of improvement. The goal of this study was to evaluate postoperative improvement, patient-reported outcomes, and patient satisfaction up to 2 years after surgical treatment for CSM, which will help optimize the current treatment strategies and effectively manage patient expectations. METHODS This was a retrospective study of prospectively collected data using the Quality Outcomes Database. The primary outcomes of interest were achievement of the minimal clinically important difference (MCID) for the numeric rating scale for neck and arm pain, modified Japanese Orthopaedic Association, Neck Disability Index, and EQ-5D scores and postoperative satisfaction (North American Spine Society scale). Early and sustained improvement was defined as MCID achievement in at least one patient-reported outcome measure (PROM) at the 3-, 12-, and 24-month follow-ups. Transient improvement was defined as MCID achievement only at the 3-month and/or 12-month follow-up but not at the 24-month follow-up. Late improvement was defined as MCID achievement in at least one PROM only at the 24-month follow-up. RESULTS There were 630 patients included in the comparative analysis. A total of 463 (73.5%) patients achieved early and sustained improvement, 105 (16.7%) patients experienced transient improvement with subsequent decline, 25 (4.0%) patients reported late improvement, and 37 (5.9%) patients did not report any clinically meaningful improvement after surgery. Patients with an anterior approach were more likely to be in the early and sustained improvement group. African American patients (OR 2.98, 95% CI 1.14–7.76; p = 0.03) were more likely to report late improvement when compared with White patients. The overall satisfaction rate at the 24-month follow-up was 87.8%. CONCLUSIONS These findings indicate that 73.5% of patients achieve early and sustained improvement, and 87.8% of patients are satisfied with surgery 24 months postoperatively.
Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design
Kotecha, Rupesh , Akdemir, Eyüb Yaşar , Blakeley, Jaishri O. , Dixit, Karan , Dunn, Ian F. , Galanis, Evanthia , Kurz, Sylvia C. , McDermott, Michael , Odia, Yazmín , Raizer, Jeffrey, Reardon, David A. , Rogers, Leland , Schiff, David , Vogelbaum, Michael A., Wen, Patrick Y. , Akdemir, Eyub Y , Blakeley, Jaishri O , Galanis, Evanthia , Galldiks, Norbert , Weller, Michael , Wen, Patrick Yung , Odia, Yazmin , Kütük, Tuğçe , Ilgın, Can , Ahluwalia, Manmeet S. , Bi, Wenya Linda , Huang, Raymond Y. , Johnson, Derek R. , Kaley, Thomas , Kamson, David , Preusser, Matthias , Rudà, Roberta , Mehta, Minesh P. , McDermott, Michael W.

Mayo Clinic

Neuro-Oncology | January 10, 2025 | Volume: 27 | Issue: 7 | Pages: 1670-1685

10.1093/neuonc/noaf009 | PMID 39807850 Get It

Abstract Background Despite advances in our understanding of the molecular underpinnings of meningioma progression and innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge. The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporary analysis, and propose a “rate of probable interest” to inform future clinical trial design and development on behalf of the Response Assessment in Neuro-Oncology meningioma group. Methods PubMed, ClinicalTrials.gov, and ASCOpubs databases were screened for clinical trials evaluating the activity of systemic therapies for adults with recurrent meningiomas. The pooled progression-free survival at 6-months and 1-year (PFS-6 and PFS-1 year) values were calculated using the random effects technique with I2 indices. Results The pooled PFS-6 and PFS-1 year rates for recurrent WHO grade 1 meningiomas were 43.6% (95% CI: 22.7-67.0%, I2 = 80%) and 21.7% (95% CI: 6.2-53.9%, I2 = 76%), and for grades 2-3 meningiomas, the PFS-6 was 38.0% (95% CI: 28.3-48.8%, I2 = 68%). In the targeted therapy group, PFS-6 and PFS-1 year rates stood at 62.0% (I2 = 58%) and 49.0% (I2 = 63%) for grade 1, while for grades 2-3 tumors, the PFS-6 rates with targeted therapy and immunotherapy were 42.1% (I² = 60%) and 46.0% (I² = 0%), respectively. The benchmarks were set at 67% and 54% for PFS-6 and PFS-1 year for grade 1 tumors, and PFS-6 of 49% for grades 2-3 tumors. Conclusions Several studies have reported outcomes in patients with recurrent meningiomas testing a variety of agents with modest, but variable and progressively increasing activity. In this context, we recommend new benchmarks for future trials to define efficacy of future investigational therapies.